Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis

Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis

ObjectiveEfgartigimod (EFG), a neonatal Fc receptor antagonist that facilitates the degradation of pathogenic immunoglobulin G, is approved for the treatment of generalized myasthenia gravis (MG). This study aims to evaluate the efficacy and safety of EFG in patients with very-late-onset myasthenia...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Zhouyi Wang, Tiancheng Luo, Deyou Peng, Xue Du, Xiaoyu Huang, Yong Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
very-late-onset myasthenia gravis
fast-acting treatment
efgartigimod
MG-ADL
clinical meaningful improvement
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579859/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579859/full

Similar Items